# Medytox Venture Investment

> Medytox Venture Investment is a VC fund in Seoul backing Biotechnology and Pharmaceutical. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 23
- Last investment: Aug 2025
- Lead investor: 4%
- Last updated: Aug 2026
- Website: http://medytoxventure.com

Medytox Venture Investment is a TIPS operator that provides opportunities and supports growth in the healthcare sector.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3M–$3.4M |
| Series A | $3.4M–$15M |
| Series B | $4k–$44M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 65% |
| Pharmaceutical | 11 | 48% |
| Medical | 6 | 26% |
| Health Care | 6 | 26% |
| Life Science | 4 | 17% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 39% |
| Series B | 5 | 22% |
| Seed | 4 | 17% |
| Series C | 4 | 17% |
| Pre-Seed | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nex Eye | Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M | Series B | Aug 13, 2025 |  |
| Dime Bio | Dime Bio is a drug development company for novel dementia treatments. | $8.2M | Series A | Mar 26, 2025 |  |
| Inventera Pharmaceuticals | Inventera Pharmaceutical is a biotechnology company that specializes in the development of imaging diagnostic contrast agents. | $13.4M | Series C | Oct 30, 2024 |  |
| AIGEN Sciences | AIGEN Sciences is an AI drug discovery platform that provides drug research and development services. | $8.8M | Series A | Oct 16, 2024 |  |
| Avelos Therapeutics | Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $12.4M | Series B | May 02, 2024 |  |
| GPCR Therapeutics | GPCR Therapeutics is a clinical-stage international biopharmaceutical firm that develops therapeutics based on proprietary GPCR data. The company was founded in 2013 and is headquartered in Seoul, South Korea. The company’s proprietary data driven approach has identified over 1000 GPCR pairs upon which drug screening campaigns can be pursued.Identification of the best GPCR pair to target for specific disease indications and patient subpopulations creates a personalized approach to combination therapy. By targeting the unique pharmacology of GPCR pairs, we aim to develop life changing treatments for cancer and other diseases. | $3.2M | Series C | Nov 29, 2023 |  |
| Zymedi | Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases. | $12.1M | Series A | May 30, 2023 |  |
| Ubix Therapeutics | Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $9.2M | Series C | Mar 28, 2023 |  |
| AinB | AinB is a biotechnology startup focused on applying artificial intelligence (AI) to the discovery and development of novel biologic drugs, particularly antibody therapeutics. By combining scientific expertise in antibody therapeutics with advanced AI capabilities, the company aims to develop innovative treatments more efficiently and strengthenKorea’s competitiveness in the global biopharmaceutical industry. |  | Seed | Mar 15, 2023 |  |
| Nex Eye | Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $15.4M | Series A | Oct 07, 2022 |  |

10 of 23 investments shown.

## Co-investors
- [Quad Asset Management](https://shizune.co/investors/profile/quad-asset-management-2471) — VC Fund, 6 deals together
- [Partners Investment](https://shizune.co/investors/profile/partners-investment) — VC Fund, 5 deals together
- [UTC Investment Co.](https://shizune.co/investors/profile/utc-investment-co) — VC Fund, 4 deals together
- [Atinum Partners](https://shizune.co/investors/profile/atinum-partners) — VC Fund, 3 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 3 deals together
- [Hana Ventures](https://shizune.co/investors/profile/hana-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)
- [Biotechnology Investors in South Korea](https://shizune.co/investors/biotechnology-investors-south-korea)
- [Biotechnology VC Funds in South Korea](https://shizune.co/investors/biotechnology-vc-funds-south-korea)
- [Biotech Investors in South Korea](https://shizune.co/investors/biotech-investors-south-korea)
- [Biotech VC Funds in South Korea](https://shizune.co/investors/biotech-vc-funds-south-korea)

## FAQ

### What does Medytox Venture Investment invest in?

Medytox Venture Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Medytox Venture Investment's check size?

Medytox Venture Investment typically joins rounds of $3M–$3.4M at Seed, $3.4M–$15M at Series A and $4k–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Medytox Venture Investment participates in.

### When did Medytox Venture Investment last invest?

The most recent investment recorded for Medytox Venture Investment closed in Aug 2025. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co